Postmenopausal Osteoporosis: A Clinical Review
- PMID: 29583083
- DOI: 10.1089/jwh.2017.6706
Postmenopausal Osteoporosis: A Clinical Review
Abstract
In postmenopausal women, osteoporotic fractures are more common than stroke, myocardial infarction, and breast cancer combined, and fractures can be costly and result in disability or death. Because there are no signs or symptoms of osteoporosis other than fracture, risk assessment is necessary to identify those at higher risk for clinical events. For women, a clinical fracture risk assessment (FRAX) is appropriate at menopause. Bone mineral density (BMD) measurement is recommended for women at age 65, and earlier for those who have risk factors. Adequate calcium, vitamin D, and weight-bearing exercise are important for bone health at all ages, and those at high risk for fracture based on BMD or FRAX should be offered medical therapy to reduce fracture risk after an appropriate medical evaluation. Bisphosphonates can accumulate in bone, so after a period of treatment, lower risk patients may be offered a period off drug therapy. However, the effects of denosumab are not sustained when treatment is discontinued, so there is no "drug holiday" with denosumab. Anabolic therapy can be offered to those with higher risk for fracture. Although rare safety concerns regarding atypical femoral fracture and osteonecrosis of the jaw have received prominent attention, for patients who are appropriately treated according to National Osteoporosis Foundation guidelines, the benefit of hip fracture risk reduction far outweighs the risk of these uncommon side effects. Accurate information for patients and shared decision-making are important for acceptance and persistent with appropriate treatment.
Keywords: bisphosphonates; bone density; denosumab; fracture; osteoporosis; postmenopausal.
Similar articles
-
The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study.Osteoporos Int. 2015 Dec;26(12):2773-83. doi: 10.1007/s00198-015-3234-7. Epub 2015 Jul 23. Osteoporos Int. 2015. PMID: 26202488 Free PMC article. Clinical Trial.
-
Fracture risk following intermission of osteoporosis therapy.Osteoporos Int. 2019 Sep;30(9):1733-1743. doi: 10.1007/s00198-019-05002-w. Epub 2019 Jun 7. Osteoporos Int. 2019. PMID: 31175404
-
Three-year denosumab treatment in postmenopausal Japanese women and men with osteoporosis: results from a 1-year open-label extension of the Denosumab Fracture Intervention Randomized Placebo Controlled Trial (DIRECT).Osteoporos Int. 2015 Feb;26(2):765-74. doi: 10.1007/s00198-014-2964-2. Epub 2014 Nov 18. Osteoporos Int. 2015. PMID: 25403903 Clinical Trial.
-
Clinical Practice. Postmenopausal Osteoporosis.N Engl J Med. 2016 Jan 21;374(3):254-62. doi: 10.1056/NEJMcp1513724. N Engl J Med. 2016. PMID: 26789873 Review.
-
Denosumab, a new pharmacotherapy option for postmenopausal osteoporosis.Curr Med Res Opin. 2013 Mar;29(3):205-16. doi: 10.1185/03007995.2013.763779. Epub 2013 Jan 25. Curr Med Res Opin. 2013. PMID: 23297819 Review.
Cited by
-
Rhizoma Drynariae-derived nanovesicles reverse osteoporosis by potentiating osteogenic differentiation of human bone marrow mesenchymal stem cells via targeting ERα signaling.Acta Pharm Sin B. 2024 May;14(5):2210-2227. doi: 10.1016/j.apsb.2024.02.005. Epub 2024 Feb 10. Acta Pharm Sin B. 2024. PMID: 38799625 Free PMC article.
-
Navigating Post-Traumatic Osteoporosis: A Comprehensive Review of Epidemiology, Pathophysiology, Diagnosis, Treatment, and Future Directions.Life (Basel). 2024 Apr 26;14(5):561. doi: 10.3390/life14050561. Life (Basel). 2024. PMID: 38792583 Free PMC article. Review.
-
Transcriptome Sequencing Identifies Abnormal lncRNAs and mRNAs and Reveals Potentially Hub Immune-Related mRNA in Osteoporosis with Vertebral Fracture.Clin Interv Aging. 2024 Feb 9;19:203-217. doi: 10.2147/CIA.S441251. eCollection 2024. Clin Interv Aging. 2024. PMID: 38352274 Free PMC article.
-
The effect of aquatic training and vitamin D3 supplementation on bone metabolism in postmenopausal obese women.J Exerc Sci Fit. 2024 Apr;22(2):127-133. doi: 10.1016/j.jesf.2024.01.002. Epub 2024 Jan 12. J Exerc Sci Fit. 2024. PMID: 38299108 Free PMC article.
-
What is known about osteoporosis research in Latin America?: A bibliometric analysis of three decades.Medicine (Baltimore). 2023 Dec 1;102(48):e36103. doi: 10.1097/MD.0000000000036103. Medicine (Baltimore). 2023. PMID: 38050309 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
